iSERA Lifesciences Ltd (COVIDH) is currently trading at 143.90 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

iSERA Lifesciences Ltd operates in the its sector sector. Review the About Company section on this page to understand its business model, revenue streams, and key products or services.

Over the past 52 weeks, iSERA Lifesciences Ltd has traded between a low of ₹7.99 and a high of ₹151.05. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

iSERA Lifesciences Ltd has a market capitalization of approximately 353.88. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

iSERA Lifesciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -4423.50 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 353.88 Cr, iSERA Lifesciences Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

iSERA Lifesciences Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of iSERA Lifesciences Ltd is -4423.50. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

They approved amendments to preferential issue disclosures, including correcting a share-allotment typo and adding detailed post-issue shareholding disclosures, with 100% votes in favour.

The board meeting is scheduled for Monday, April 20, 2026.